NASDAQ · BDTX
Healthcare · Biotechnology
$1.96
Up+$0.02 (+1.02%)
Updated Sep 12, 2026, 12:59 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BDTX closed at $1.96 after 19 trading sessions, down 2.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.06 | $2.06 | $1.92 | $1.96 | 677.92K |
| Sep 9, 2026 | $2.09 | $2.1492 | $2.065 | $2.10 | 402.59K |
| Sep 8, 2026 | $2.09 | $2.13 | $2.0719 | $2.10 | 370.04K |
| Sep 4, 2026 | $2.08 | $2.145 | $2.0609 | $2.12 | 324.72K |
| Sep 3, 2026 | $2.15 | $2.1655 | $2.06 | $2.10 | 609.84K |
| Sep 2, 2026 | $2.08 | $2.155 | $2.05 | $2.14 | 561.28K |
| Sep 1, 2026 | $2.09 | $2.11 | $2.02 | $2.04 | 759.13K |
| Aug 31, 2026 | $2.22 | $2.225 | $2.10 | $2.10 | 509.28K |
| Aug 28, 2026 | $2.28 | $2.29 | $2.17 | $2.23 | 522.04K |
| Aug 27, 2026 | $2.26 | $2.32 | $2.24 | $2.27 | 458.91K |
| Aug 26, 2026 | $2.21 | $2.29 | $2.16 | $2.27 | 491.29K |
| Aug 25, 2026 | $2.19 | $2.245 | $2.185 | $2.24 | 417.76K |
| Aug 24, 2026 | $2.22 | $2.22 | $2.13 | $2.155 | 345.32K |
| Aug 21, 2026 | $2.15 | $2.26 | $2.15 | $2.21 | 656.73K |
| Aug 20, 2026 | $2.17 | $2.19 | $2.08 | $2.15 | 1.14M |
| Aug 19, 2026 | $2.08 | $2.21 | $2.08 | $2.19 | 827.22K |
| Aug 18, 2026 | $2.05 | $2.08 | $2.02 | $2.06 | 474.81K |
| Aug 17, 2026 | $2.01 | $2.085 | $2.01 | $2.05 | 389.8K |
| Aug 14, 2026 | $2.01 | $2.045 | $1.9601 | $2.02 | 330.41K |
The latest Smart Investors Daily articles mentioning BDTX.
BDTX research
Company profile and research snapshot.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BTIG | Buy | — |
| Mar 17, 2026 | Wedbush | Outperform | — |
| Jan 16, 2026 | Piper Sandler | Overweight | — |
| Dec 4, 2025 | Guggenheim | Neutral | — |
| Oct 16, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · May 7, 2026
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
Finnhub · May 7, 2026
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Finnhub · May 7, 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
Benzinga · Apr 29, 2026
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDTX.
